【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2015-2025
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation Of The Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2014
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
3.5 Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025
4. The Retinal Disorder Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Leading Products In The Retinal Disorder Drugs Market, 2014
4.2 Retinal Disorders: Market Trends And Developments, 2015
4.2.1 The Rise And Rise Of Lucentis
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales And ThromboGenics’ Efforts To Reverse It
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2015-2025
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Lucentis (ranibizumab) – Roche/ Novartis
4.5.1 Lucentis: Sales Forecast 2015-2025
4.5.2 Less Frequent Dosing Approved In US For Lucentis
4.5.3 New Indications For Lucentis
4.5.4 Possible Combination Therapy Involving Lucentis
4.6 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.6.1 Recent Approvals For Eylea
4.6.2 Eylea: Sales Forecast 2015-2025
4.6.3 Possible Combination Therapies Involving Eylea
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2015-2025
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2015-2025
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2015-2025
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2015-2025
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
5.1.1 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
5.1.2 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.1.3 Topical NSAIDs Launched: Prolensa and Ilevro
5.2 Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
5.2.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.4 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.4.1 Pataday: Sales Forecast 2015-2025
5.4.2 Impending Generic Competition For Patanol And Pataday
5.4.3 Approval Of Pazeo Solution
5.4.4 Patanol: Sales Forecast 2015-2025
5.5 Vigamox (moxifloxacin) – Alcon (Novartis)
5.5.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.5.2 Moxeza: A Next-Generation Form of Vigamox
5.5.3 Vigamox: Sales Forecast 2015-2025
5.6 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.6.1 The Development And Commercialisation Of TobraDex ST
5.6.2 TobraDex: Sales Forecast 2015-2025
5.7 Bromday (bromfenac) – Valeant
5.7.1 Prolensa: A New Formulation Of Bromfenac
5.7.2 Competition From Ilevro/Nevanac
5.7.3 Bromday: Sales Forecast 2015-2025
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2015-2025
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2015-2025
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2015-2025
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025
6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2014
6.2 Glaucoma Drugs: Market Trends And Developments, 2015
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.2.4 Simbrinza: First Beta-Blocker-Free Combination
6.3 Glaucoma Drugs: Market Forecast 2015-2025
6.3.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs For The Treatment Of Glaucoma
6.5 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.5.1 Lumigan And Ganfort: Sales Forecast 2015-2025
6.6 Xalatan And Xalacom (latanoprost) – Pfizer
6.6.1 Xalatan/Xalacom: Sales Forecast 2015-2025
6.7 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.7.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
6.8 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.8.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
6.9 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.9.1 Divestment Agreement With Santen And Akorn
6.9.2 Trusopt: Sales Forecast 2015-2025
6.9.3 Cosopt And Cosopt PF: Sales Forecast 2015-2025
6.10 Azopt (brinzolamide) – Novartis
6.10.1 Azopt: Sales Forecast 2015-2025
6.11 Tapros (tafluprost) – Santen
6.11.1 Tapros: Sales Forecast 2015-2025
6.12 Zioptan (tafluprost) – Akorn
6.12.1 Zioptan: Sales Forecast 2015-2025
6.13 Other Glaucoma Drugs: Sales Forecast 2015-2025
7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2014
7.2 Dry Eye Drugs: Market Trends And Developments, 2015
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2015-2025
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis Patent Elongation
7.5.2 Restasis: Sales Forecast 2015-2025
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2015-2025
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2015-2025
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2015-2025
7.9 Other Dry Eye Drugs: Sales Forecast 2015-2025
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.1.1 Hetlioz: Sales Forecast 2015-2025
8. Leading National Markets For Ophthalmic Drugs, 2015-2025
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Mexican Healthcare Reform: Introducing Seguro Popular
8.11.2 Are Multinationals Waking Up To Mexico’s Market Potential?
8.11.3 Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025
9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.1.1 Leading Companies In The Ophthalmic Drugs Market, 2015
9.1.2 Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 Novartis (Alcon)
9.2.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.2.2 Novartis: Sales Forecast 2015-2025
9.2.3 Novartis: Ophthalmic Drugs Development Pipeline, 2015
9.2.4 Novartis: Recent Developments
9.2.4.1 Novartis Restructures Following Strategic Review
9.2.4.2 Novartis Licenses Ophthotech’s Fovista
9.3 Allergan (Actavis)
9.3.1 Allergan: Ophthalmic Drugs Portfolio
9.3.2 Allergan: Recent Developments
9.3.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.3.2.2 How Real Is The Threat Of Generic Restasis?
9.3.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.3.3 Allergan: Sales Forecast 2015-2025
9.3.4 Allergan: Ophthalmic Drugs Development Pipeline, 2015
9.4 Roche
9.4.1 Roche: Ophthalmic Drugs Portfolio, 2015
9.4.1.1 Lucentis: US Sales Forecast 2015-2025
9.4.2 Roche: Sales Forecast 2015-2025
9.4.3 Roche: Ophthalmic Drugs Development Pipeline, 2015
9.5 Santen
9.5.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.5.2 Santen: Recent Developments
9.5.2.1 Santen Acquires Novagali Pharma
9.5.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.5.3 Santen: Sales Forecast 2015-2025
9.5.4 Santen: Ophthalmic Drugs Development Pipeline, 2015
9.6 Regeneron
9.6.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.6.2 Regeneron: Recent Developments
9.6.2.1 Expanding Indications For Eylea
9.6.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.6.3 Regeneron: Sales Forecast 2015-2025
9.6.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2015-2025
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2015
9.8 Pfizer
9.8.1 Pfizer: Ophthalmic Drugs Portfolio, 2015
9.8.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.8.1.2 Macugen – Valeant/Pfizer
9.8.2 Pfizer: Recent Developments
9.8.2.1 Pfizer Attempts to Acquire AstraZeneca
9.8.3 Pfizer: Sales Forecast 2015-2025
9.8.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2015
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2015-2025
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2015-2025
9.10.3 Senju: Ophthalmic Drugs Development Pipeline, 2015
9.10.3.1 Y 39983 (SNJ 1656)
9.10.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2015-2025
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2015
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.2.2 Retinal Disorders: Filed or Recently Launched
10.2.2.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.2.2.2 Lipidil (fenofibrate) – Abbott
10.2.2.3 Iluvien (fluocinolone) – Alimera Sciences
10.2.3 Drugs In Phase 3 Development For Retinal Disorders
10.2.3.1 Fovista and Zimura – Ophthotech Corporation
10.2.3.2 Lampalizumab (anti-Factor D Fab) – Roche
10.2.3.3 MC-1101 (hydralazine) – MacuCLEAR
10.2.3.4 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.2.3.5 UF-021 (unoprostone) – R-Tech Ueno
10.2.4 Drugs In Phase 2 Development For Retinal Disorders
10.2.4.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.2.4.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.2.4.3 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.2.4.4 AGN208397 (beclomethasone) – Allergan
10.2.4.5 CPC 551 – Colby Pharmaceutical
10.2.4.6 Darapladib And GSK933776 – GlaxoSmithKline
10.2.4.7 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.2.4.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.2.4.9 iSONEP (sonepcizumab) – Lpath
10.2.4.10 LFG316 (anti-C5 mAb) – Novartis
10.2.4.11 Novadur (Intravitreal brimonidine implant) – Allergan
10.2.4.12 Optina (danazol) – Ampio Pharmaceuticals
10.2.4.13 PF-655 (synthetic siRNA) – Quark/Pfizer
10.2.4.14 Premiplex (protein replacement therapy) – Shire
10.2.4.15 Renexus (ciliary neurotrophic factor) – Neurotech
10.2.4.16 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.2.4.17 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.2.5 Drugs In Phase 1 And Pre-clinical Development For Retinal Disorders
10.2.5.1 BDM-E – BioDiem
10.2.5.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.2.5.3 NS2 (aldehyde trap) – Aldeyra Therapeutics
10.2.5.4 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.2.5.5 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.2.5.6 QLT091001 (synthetic retinoid) – QLT
10.3 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.1.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.3.1.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.3.1.3 LE-MPP (loteprednol etabonate) – Kala
10.3.2 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.2.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.3.2.2 FST-100 (povidone-iodine/dexamethasone) – ForeSight Biotherapeutics
10.3.2.3 NVC-422 (auriclosene) – NovaBay
10.3.2.4 Sarilumab – Regeneron
10.3.2.5 V404 PDS – ForSight VISION
10.3.3 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.3.3.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.4 Drugs For Glaucoma: Development Pipeline, 2015
10.4.1 Drugs In Phase 2&3 Development For Glaucoma
10.4.1.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.4.1.2 AMA0076 (ROCK inhibitor) – Amakem
10.4.1.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.4.2 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.5 Drugs For Dry Eye: Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dry Eye
10.5.1.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.5.1.2 Lifitegrast (integrin antagonist) – Shire
10.5.1.3 MIM-D3 (tyrosine kinase receptor antagonist) – Valeant
10.5.1.4 SI-614 (modified hyaluronate) – Seikagaku
10.5.2 Drugs In Phase 2 Development For Dry Eye
10.5.2.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.6 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.6.1 Brimonidine For Eye Whitening – Valeant
10.6.2 GS-101 (aganirsen) – Gene Signal
10.6.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-2025
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 A Healthy R&D Pipeline
11.2.1.2 Advances In Drug Delivery Technologies
11.2.1.3 Support For Reimbursement And Payment Approvals
11.2.1.4 Gene Therapy And RNA Interference Technology
11.2.1.5 New Ophthalmic Therapeutic Applications For Drugs
11.2.1.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.2.1.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.2.2 Weaknesses
11.2.2.1 Patient Adherence To Treatment
11.2.2.2 High Treatment Burden On Patients And Healthcare Providers
11.2.2.3 Under-Diagnosis And Under-Treatment
11.2.3 Opportunities
11.2.3.1 Sustained-Release Ocular Implants
11.2.3.2 The Impact Of A Rapidly Ageing Global Population
11.2.3.3 Increasing Prevalence Of Eye Diseases And Diabetes
11.2.3.4 Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In Prevalence
11.2.3.5 Unmet Clinical Need In Many Disease Areas
11.2.3.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.2.4 Threats
11.2.4.1 Intensifying Price Regulation In The Market
11.2.4.2 Generic Competition – Likely Erosion Of Sales For Market Leading Brands
11.2.4.3 Rising Costs Of R&D
11.2.4.4 Biosimilars – A Potent Threat To Ophthalmic Drugs’ Success
11.3 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.3.1 Threat of New Entrants
11.3.2 Rivalry Among Competitors
11.3.3 Power of Suppliers
11.3.4 Threat of Substitutes
11.3.5 Power of Buyers
12. Expert Opinions from Our Primary Research
12.1 Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate Communications & Investor Relations At ThromboGenics nv
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
12.1.2 Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
12.1.3 The Need To Embrace Novel Treatments
12.1.4 Future Plans For Jetrea
12.1.5 Expanding Treatment Indications And Strategies For Maximising Product Potential
12.1.6 Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
12.1.7 Development Efforts For Jetrea In Retinal Vein Occlusion
12.1.8 Future Prospects For The Ophthalmic Drugs Market
12.2 Interview With A Spokesperson From Akorn Pharmaceuticals
12.2.1 New Formulation Strategies For Cosopt, Zioptan And Azasite
12.2.2 Expansion Plans For Akorn’s Ophthalmic Portfolio
12.2.3 Tackling Key Unmet Needs Within Ophthalmics
12.2.4 Akorn’s Future Plans For Growth
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Ophthalmic Drugs In 2014
13.3 Leading Regions In The Ophthalmic Drugs Market In 2014
13.4 Leading Companies In The Ophthalmic Drugs Market, 2014
13.5 What Does The Future Hold For Ophthalmic Drugs?
【レポート販売概要】
■ タイトル：眼科用薬の世界市場：ドライアイ、緑内障、網膜障害、アレルギー性・炎症性・感染性眼科疾患■ 英文：Ophthalmic Drugs Market Forecast 2015-2025 : Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5072208
■ 調査対象地域：グローバル
- スマート複合材料の世界市場2015-2022Smart composites leverage the commercial success of the composite technology model and apply it specifically to smart materials. In regular composites two materials are combined to create a new material with functionality that is significantly different to the original materials. Typically, a smart composite is a smart material embedded in polymer, textiles, metal or concrete. In a few cases, smar …
- 世界のポリカーボネート市場動向（2014-2018）TechNavio's analysts forecast the Global Polycarbonate market to grow at a CAGR of 5.05 percent over the period 2013-2018. One of the key factors contributing to this market growth is the expansion of production capacities by vendors. The Global Polycarbonate market has also been witnessing the increasing production of products with recycled polycarbonate content However, the decline of optical me …
- 海洋安全用救急箱の世界市場ABSTRACTAbout Ocean Safety First Aid Kit First aid is the provision of immediate or emergency treatment to a person with an injury or illness before the complete medical aid. By performing certain procedures and following certain guidelines, it is possible to provide basic treatment to reduce the gravity of an acute injury. Ocean safety first-aid kits include safety medication for the first-degree …
- BRIC地域の人工心臓弁処置動向（～2020）BRIC Prosthetic Heart Valve Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Prosthetic Heart Valve Procedures Outlook to 2020", provides key procedures data on the BRIC Prosthetic Heart Valve Procedures. The report provides procedure volumes within market categories - Conventional Mitral Valve (Mitral Valve Re-repair, Mitral Valve Annuloplasty, Mitral Valve Repair, Mitral Valve R …
- 電動三輪車の世界市場2016-2020About Electric Trikes The traditional two-wheeled motorcycle dominates the market because such machines are tested and proven mechanisms delivering mileage performance. Another type of vehicle is the trike, the three-wheeled motorcycle, which is known for its increased stability and safety of the rider. These motorcycles are equipped with advanced features to increase the driving pleasure and for …
- ポリアクリルアミドの世界市場2017-2021About Polyacrylamide Polyacrylamide is an acrylic resin compound that is soluble in water. It is generally produced by the polymerization of acrylamide monomer subunits. Acrylamide is an odorless and colorless, water-soluble chemical compound. It is produced by the hydration of acrylonitrile and is commonly used in the synthesis of polyacrylamide polymers. Generally, acrylamide polymer is non-haza …
- 世界の造影剤/コントラスト剤市場：種類別（ヨウ素化、ガドリニウム、バリウム、およびマイクロバブル）、処置別（X線/ CT、MRI、および超音波）、用途別（放射線学、インターベンショナル放射線学、インターベンショナル心臓学）、地域別“Contrast media/contrast agents market is projected to grow at a CAGR of 3.8%.” The global contrast media/contrast agents market is projected to reach USD 6.0 billion by 2024 from an estimated USD 5.0 billion in 2019, growing at a CAGR of 3.8% during the forecast period. The contrast media market has witnessed various advancements in products and their approvals to meet the needs of patients and r …
- 産業用自動データ取込/認識装置の世界市場About automatic data capturing and identification systems Data capture is the mechanism of identifying and extracting data from scanned products for further processing. Automatic data capture refers to collecting data using automated data capture equipment, such as barcode readers/scanners, magnetic stripe readers, and cameras, or by using RFID technology. It requires no manual typing or punching …
- Legacy Oil + Gas Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Legacy Oil + Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Legacy Oil + Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- スマートサーフェスの世界市場2015-2022In this report, NanoMarkets identifies the emerging market opportunities for smart surfaces across a wide range of applications. Smart surfaces are capable of rearranging their morphology or composition in response to changes of the ambient environment. We expect smart surfaces to capitalize on the recent commercial successes of smart coatings and note both the extensive R&D in the field of smart …
- 世界のリーファー輸送市場2014/15New and improved for 2014, including greater analysis of reefer container trades. Key areas covered in this report include: Perishable product trade statistics NEW Annual reefer containerised trade route matrix NEW Top 20 containership operators by reefer teu capacity Specialised reefer and freezer fleet analysis and forecasts up to 2018 EXPANDED Containership fleet profile, operators and financia …
- 世界の苛性ソーダ市場2015The Global Caustic Soda Industry Report 2015 is a professional and in-depth study on the current state of the Caustic Soda industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Caustic Soda market analysis is provided for the international markets including development trends, competitive landscape analy …
- メカニカルシール（軸封装置）の世界市場2015-2019Mechanical seals are widely used in the oil and gas, chemical, water and wastewater, and power industries as they prevent leakage of industrial contaminants as well as corrosion and fatigue that can reduce the efficiency and cycle life of the equipment. They also play a crucial role in the production and transportation process in the oil and gas industry, making it a significant end-user of this m …
- ヘルスケア産業用クリーンルーム装置/消耗品/建設/技術の世界市場The increasing focus for the safety and quality of healthcare products, working personnel, and environment propels the use of cleanrooms in healthcare industry across the globe. Today, the increasing product innovation and automation of cleanrooms are developing the better cleanroom solutions for healthcare industry. In this report, the global healthcare cleanrooms market is broadly segmented by t …
- フリップチップの世界市場2018-2022About Flip Chip Flip chip is a type of packaging type, which interconnects chip and package carriers or substrates using a conductive bump. Conductive bumps are placed on the die surface, which is flipped to connect the substrate directly. Technavio’s analysts forecast the Global Flip Chip Market Market to grow at a CAGR of 6.22% during the period 2018-2022. Covered in this report The report cover …
